Pembrolizumab as adjuvant therapy in non-small-cell lung cancer

Affiliations

Comment

Steven Sorscher. Lancet Oncol. 2022 Dec.

. 2022 Dec;23(12):e529.

doi: 10.1016/S1470-2045(22)00682-9.

¹ 1821 Georgia Ave, Winston-Salem, NC 27104, USA. Electronic address: ssorscher1@gmail.com.

No abstract available

Conflict of interest statement

I was formerly employed by Invitae.

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S; EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators. O'Brien M, et al. Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12. Lancet Oncol. 2022. PMID: 36108662 Clinical Trial.